InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models that can be used to obtain quick and informed answers to several “What if” scenarios. This opens the door to a whole new concept of personalized medicine enabling the consolidation of multidisciplinary efforts (computational modelling, materials science and engineering, systems biology). InSilc is expected to transform the Stent Biomedical Industry, by including all available physiological and biological knowledge and by capturing the features of individual patients, while in parallel introduce the concept of the patient-specific model InSilc will enable the simulation of a number of patient-specific factors and take into account the variability among individuals, which affects the outcomes of the candidate drug-eluting BVS implantation. “Virtual” patients would be given a “virtual” drug-eluting BVS, allowing observations, through computational simulations, the performance of the scaffold, assess and quantify the intended effect, with a much deep understanding than normal trials can provide, without inducing adverse effects and undesirable clinical outcomes, that might be potentially dangerous for the patient.

The challenge is twofold. By integrating all scattered information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate, reliable and robust information to the Stent Biomedical Industry, (ii) assist the Interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance, such as in-stent restenosis (ISR) and stent thrombosis (ST). InSilc will develop the technology, methods, protocols and standards required to make ISCT for drug-eluting BVS a reality. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, address the ethical issues by reducing, refining, and partially replacing the human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.

Figure18_new logo